Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial

Khanna, Dinesh; Denton, Christopher P.; Jahreis, Angelika; Laar, Jacob M van; Frech, Tracy; Anderson, Marina; Baron, Murray; Chung, Lorinda; Fierlbeck, Gerhard; Lakshminarayanan, Santhanam; Allanore, Yannick; Pope, Janet; Riemekasten, Gabriela; Steen, Virginia D.; Müller‐Ladner, Ulf; Lafyatis, Robert; Stifano, Giuseppina; Spotswood, Helen; Chen-Harris, Haiyin; Dziadek, Sebastian; Morimoto, Alyssa; Sornasse, Thierry; Siegel, Jeffrey; Fürst, Daniel E.

doi:10.1016/s0140-6736(16)00232-4

Cited by 568 publications

(436 citation statements)

References 37 publications

Supporting

Mentioning

379

Contrasting

Unclassified

Order By: Relevance

“…In a recent double-blind, placebo-controlled trial, treatment with tocilizumab (an interleukin 6 receptor-α inhibitor) was associated with a greater reduction of skin thickening at 24 weeks than placebo. 29 Several studies have supported autologous stem cell transplantation as a viable treatment option for patients with poor prognosis SSc. 30,31 Compared with the existing gold standard of cyclophosphamide, treatment may stabilise/improve skin sclerosis and internal organ involvement, and is associated with a long-term survival benefit.…”

Section: Emerging Treatment Optionsmentioning

confidence: 99%

Early diagnosis and management of systemic sclerosis

Hughes¹

2018

Prescriber

View full text Add to dashboard Cite

show abstract

Section: Emerging Treatment Optionsmentioning

confidence: 99%

Early diagnosis and management of systemic sclerosis

Hughes¹

2018

Prescriber

View full text Add to dashboard Cite

show abstract

“…У 28% больных основной группы и у 7% группы плацебо было отмечено улучшение ≥0,22 по опроснику оценки состояния здоровья (индекс инвалидизации; р=0,01). У пациентов, получавших ТЦЗ, наблюдалось заметное (хотя и статистически незначи-мое) улучшение показателей по глобальной визуальной ана-логовой шкале и опроснику функциональной оценки лече-ния хронического заболевания [26]. Серьезные инфекцион-ные НЯ чаще регистрировались в группе, получавшей ТЦЗ, чем в группе плацебо.…”

Section: рис 1 мскт органов грудной клетки больной 61 года выраженunclassified

Diagnosis and treatment of interstitial lung disease in scleroderma systematica

Ананьева¹

2018

RJTAO

View full text Add to dashboard Cite

Поражения респираторного тракта при системных имму-новоспалительных ревматических заболеваниях (СИРЗ) включают в себя широкий спектр клинических синдромов и симптомов. К основным проявлениям собственно СИРЗ от-носят поражение плевры и воздухоносных путей, интерсти-циальные пневмонии, диффузные альвеолярные геморрагии

show abstract

“…The elevated IL-6 levels that remained after Retisert implantation (and in stage IV disease) were an attractive target (Supplemental Figure 2C and Figure 3, A and B), since IL-6 is linked to many fibrotic diseases (21-28), including ocular fibrosis associated with proliferative diabetic retinopathy (29) and proliferative vitreoretinopathy (30). Tocilizumab, which targets IL-6 (anti-IL-6), is used to treat severe cases of rheumatoid arthritis, systemic juvenile idiopathic arthritis, and is currently in trial for the treatment of systemic sclerosis (28,31). So, for a special case of stage IV NIV, we considered repurposing tocilizumab.…”

Section: L I N I C a L M E D I C I N Ementioning

confidence: 99%

Therapeutic drug repositioning using personalized proteomics of liquid biopsies

Vélez¹,

Bassuk²,

Colgan³

et al. 2017

JCI Insight

View full text Add to dashboard Cite

IntroductionAfter spending several billion dollars and a decade or more in development and clinical trial, only approximately 10% of new drugs show efficacy and reach the market for patient use. This apparent inefficiency, however, masks enormous opportunities to repurpose existing drugs to treat diseases for which they were not originally intended, especially diseases with limited therapeutic options (1, 2). Therapies for inflammatory diseases are an attractive choice for drug repositioning because of the complexity of the immune response, the hit-or-miss nature of treatment (which is often by trial and error), and the number of traditional drugs and new biologics for inflammatory diseases.Determining which drugs to reposition, however, is not trivial. Among a heterogeneous patient population that seems affected by the same autoimmune condition, one cannot be sure if the disease is in fact the same, or at what progressive stage a patient is presenting. Currently, most predictions of patients that would benefit from drug repositioning are drawn from retrospective computational methods, genomic analyses, BACKGROUND. In patients with limited response to conventional therapeutics, repositioning of already approved drugs can bring new, more effective options. Current drug repositioning methods, however, frequently rely on retrospective computational analyses and genetic testing -time consuming methods that delay application of repositioned drugs. Here, we show how proteomic analysis of liquid biopsies successfully guided treatment of neovascular inflammatory vitreoretinopathy (NIV), an inherited autoinflammatory disease with otherwise poor clinical outcomes.

show abstract

Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial

Abstract: F Hoffmann-La Roche, Genentech.

Cited by 568 publications

References 37 publications

Early diagnosis and management of systemic sclerosis

Early diagnosis and management of systemic sclerosis

Diagnosis and treatment of interstitial lung disease in scleroderma systematica

Therapeutic drug repositioning using personalized proteomics of liquid biopsies

Contact Info

Product

Resources

About